Glofitamab,Obinutuzumab,Tocilizumab
roche
['glofitamab', 'lymsm']
day 2 starting off with exciting updates on glofitamab - excited to read this later but the durable responses presented today in the r/r setting are intriguing although need to get a better sense of who may benefit and enter the initial cr group #ash22 #lymsm 
Heme/Onc fellow @UChicagoMed, alumna of @MedChiefs @UCSFMedicine @Harvard. Views are my own.